Spencer Ryan K, Kreutzer Adam G, Salveson Patrick J, Li Hao, Nowick James S
Department of Chemistry, University of California, Irvine, Irvine, California 92697, United States.
J Am Chem Soc. 2015 May 20;137(19):6304-11. doi: 10.1021/jacs.5b01673. Epub 2015 May 12.
Amyloid diseases such as Alzheimer's disease, Parkinson's disease, and type II diabetes share common features of toxic soluble protein oligomers. There are no structures at atomic resolution of oligomers formed by full-length amyloidogenic peptides and proteins, and only a few structures of oligomers formed by peptide fragments. The paucity of structural information provides a fundamental roadblock to understanding the pathology of amyloid diseases and developing preventions or therapies. Here, we present the X-ray crystallographic structures of three families of oligomers formed by macrocyclic peptides containing a heptapeptide sequence derived from the amyloidogenic E chain of β2-microglobulin (β2m). Each macrocyclic peptide contains the heptapeptide sequence β2m63-69 and a second heptapeptide sequence containing an N-methyl amino acid. These peptides form β-sheets that further associate into hexamers, octamers, and dodecamers: the hexamers are trimers of dimers; the octamers are tetramers of dimers; and the dodecamers contain two trimer subunits surrounded by three pairs of β-sheets. These structures illustrate a common theme in which dimer and trimer subunits further associate to form a hydrophobic core. The seven X-ray crystallographic structures not only illustrate a range of oligomers that a single amyloidogenic peptide sequence can form, but also how mutation can alter the size and topology of the oligomers. A cocrystallization experiment in which a dodecamer-forming peptide recruits a hexamer-forming peptide to form mixed dodecamers demonstrates that one species can dictate the oligomerization of another. These findings should also be relevant to the formation of oligomers of full-length peptides and proteins in amyloid diseases.
诸如阿尔茨海默病、帕金森病和II型糖尿病等淀粉样疾病具有毒性可溶性蛋白质寡聚体的共同特征。由全长淀粉样生成肽和蛋白质形成的寡聚体没有原子分辨率的结构,只有少数由肽片段形成的寡聚体结构。结构信息的匮乏为理解淀粉样疾病的病理学以及开发预防或治疗方法提供了一个基本障碍。在此,我们展示了由含有源自β2-微球蛋白(β2m)淀粉样生成E链的七肽序列的大环肽形成的三类寡聚体的X射线晶体学结构。每个大环肽包含七肽序列β2m63 - 69和另一个含有N - 甲基氨基酸的七肽序列。这些肽形成β - 折叠,进一步缔合形成六聚体、八聚体和十二聚体:六聚体是二聚体的三聚体;八聚体是二聚体的四聚体;十二聚体包含由三对β - 折叠包围的两个三聚体亚基。这些结构说明了一个共同的主题,即二聚体和三聚体亚基进一步缔合形成疏水核心。这七个X射线晶体学结构不仅展示了单个淀粉样生成肽序列可以形成的一系列寡聚体,还展示了突变如何改变寡聚体的大小和拓扑结构。一个共结晶实验,其中形成十二聚体的肽招募形成六聚体的肽以形成混合十二聚体,证明一种物质可以决定另一种物质的寡聚化。这些发现也应该与淀粉样疾病中全长肽和蛋白质寡聚体的形成相关。